IFRX 2.24 (+5.16%)
NL0012661870BiotechnologyBiotechnology

InflaRx (IFRX) Stock Highlights

2.24 | +5.16%
2024-12-21 06:55:43
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Statistics

Range Today
2.08 2.29
Volume Today 88.7K
Range 1 Year
1.16 2.82
Volume 1 Year 48.65M
Range 3 Year
0.78 7.25
Volume 3 Year 318.23M
Range 10 Year
0.78 53.1
Volume 10 Year 962.55M

Highlights

Market Capitalization 91.86M (small)
Floating Shares 48.83M
Current Price 2.24
Price To Earnings -1.78
Price To Revenue 698.73
Price To Book 1.12
Earnings Per Share -0.89
Payout Ratio 0%

Performance

Latest +5.16%
1 Month +12%
3 Months +49.33%
6 Months +56.64%
1 Year +57.75%
3 Years -46.02%
5 Years -43.29%
10 Years -85.07%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.